| Effect | None |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 37 |
| Sex | Male |
| Age Range | 45-64 |
| Body Types | Overweight |
In men with a history of colon cancer given 80mg Promensil (40mg twice daily) over the course of eight weeks failed to significantly reduce IGF-1 (free or total) and IGF-II while all three binding proteins (IGFBP1-3) were also similarly not affected. In controlling for those who produced equol (23% of sample; those with serum equol higher than 83nM) there was a decrease in total IGF-1 whereas the binding proteins were still unaffected.
